Navigation Links
Study finds environmental tests help predict hospital-acquired Legionnaires' disease risk
Date:8/22/2007

PITTSBURGH, Aug. 22 A new study spearheaded by the University of Pittsburgh School of Medicine has determined that environmental monitoring of institutional water systems can help to predict the risk of hospital-acquired Legionella pneumonia, better known as Legionnaires disease. Reported recently in the journal Infection Control and Hospital Epidemiology, the 20-hospital study also calls for reconsideration of the current national infection-control policy to include routine testing of hospital water systems for Legionella, the bacterial group associated with Legionnaires.

Only those hospitals that had high levels of Legionella bacteria in their water systems had patients who contracted Legionnaires disease, senior author Victor L. Yu, M.D., professor of medicine at the University of Pittsburgh School of Medicine, said of the study, which involved hospitals in 14 states. Proactive monitoring of the hospital water supply alerted physicians to the hidden risk of Legionnaires disease for their patients.

Legionella bacteria first were identified as causing pneumonia in 1976 following an outbreak among attendees at an American Legion convention at a Philadelphia hotel, resulting in the name Legionnaires disease. With an average fatality rate of 28 percent, Legionnaires is estimated to be responsible for up to 20,000 cases a year in the United States, many of them hospital-acquired. Currently, the U.S. Centers for Disease Control and Prevention recommends that hospitals and other health care institutions monitor patients for pneumonia incidence before doing environmental surveillance of water systems that can harbor the bacteria.

Based in part on our work, and in collaboration with the Allegheny County Health Department and the Three Rivers Association for Professionals in Infection Control, the development of proactive guidelines for hospital-acquired Legionnaires disease prevention has led to the virtual disappearance of this infection in Pittsburgh, said study first author Janet Stout, Ph.D., research assistant professor in Pitts department of civil and environmental engineering. We first reported the connection between hospital water supply and these infections in 1982.

For this investigation, Drs. Yu, Stout and colleagues evaluated samples of hospital system water at 20 facilities across the country from 2000 to 2002. Water samples were retrieved from at least 10 separate sites at each hospital on multiple occasions over the two-year period. When cases of Legionnaires were identified, patient urine and sputum samples from 12 of the hospitals were tested to determine classification of Legionella, which has at least 48 strains.

The researchers found that 14 (70 percent) of hospital water systems tested positive for Legionella species, and that six (43 percent) positive hospitals had high-level colonization. Legionnaires cases were among the 633 patients with hospital-acquired pneumonia whose urine or sputum samples were tested for Legionella bacteria. All were traced to hospitals with high-level colonization.

Our study provides much-needed evidence to support a national policy change to include routine environmental surveillance of health care facility water systems along with stringent clinical monitoring of patients, said Dr. Stout, who estimates that 39,000 people have died of Legionnaires since 1982. We think this long overdue approach should be adopted by infection control and infectious disease practitioners nationwide.


'/>"/>

Contact: Michele Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related biology news :

1. Bioartificial kidney under study at MCG
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. W.M. Keck Foundation funds study of friendly microbes
4. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
5. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
6. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
7. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
8. Study Links Ebola Outbreaks To Animal Carcasses
9. Genome-wide mouse study yields link to human leukemia
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
Breaking Biology Technology: